As the global economy mends, the 2021 growth of Sorafenib will have significant change from previous year. According to our (LP Information) latest study, the global Sorafenib market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Sorafenib market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Sorafenib market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Sorafenib market, reaching US$ million by the year 2028. As for the Europe Sorafenib landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Sorafenib players cover Bayer, Natco Pharma, Cipla, and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Sorafenib market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Patented Drugs
Generic Drugs
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Kidney Cancer
Liver Cancer
Thyroid Cancer
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Bayer
Natco Pharma
Cipla
Mylan